Benjamin Brown BS

Benjamin Brown is Co-Founder and Executive Director of the American Society of Pharmacovigilance, a member-based organization redefining how America thinks about adverse drug events. In his role, he sets the organization’s vision, oversees the strategic direction of the Society, supports its leaders, and forges cross-sector partnerships, collaborations, and coalitions uniting key stakeholders to address shared challenges and advance the promise of precision medicine. In 2020, he co-created and founded the Standardizing Laboratory Practices in Pharmacogenomics Initiative (STRIPE), which is the nation’s first and only Collaborative Community for Pharmacogenomics, recognized and supported by the FDA’s Center for Devices and Radiological Health and Center for Drug Evaluation and Research. Additionally, he is actively involved in pharmacogenomics at the National Institute of Health’s, National Human Genome Research Institute, serving as a member of the PGX working group (ISCC-PEG) to improve genomic literacy of healthcare providers and enhance the effective practice of clinical genomic medicine by facilitating interactions among the key stakeholders in genomics education.